A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Rosiglitazone is currently used in the treatment of type 2 diabetes and is suggested to be a perspective medicine for neurodegenerative diseases as a regulator of inflammation in central nervous system. The present work is focused on rosiglitazone effect on inflammatory response stimulated by lipopolysaccharide (LPS) in rat astroglioma cells line C6 and primary rat astrocytes. We have estimated the effect at the cyclooxygenase 2 (COX-2) mRNA expression level by qPCR and at the level of signaldoi:10.5281/zenodo.31150 fatcat:ulyu5iqszjegdnrafxoqjbutky